NcXHF

AHMAD A. TARHINI
immune cells within human colorectal tumors predict clinical outcome.
Science. 2006;313:1960-1964.
40. Tarhini AA, Lin Y, Lin HM, et al. Immune related pathways/genes identifıed
through tumor gene expression profıling can signifıcantly predict
neoadjuvant ipilimumab clinical benefıt. Paper presented at: 105th Annual
Meeting of the AACR; April 2014; San Diego, CA. Abstract 2911.
41. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human
cancer. Nature. 2002;417:949-954.
42. Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent
prognostic factor in metastatic melanoma. Cancer. 2012;118:
4014-4023.
43. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib
in melanoma with BRAF V600E mutation. New Engl J Med.
2011;364:2507-2516.
44. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated
metastatic melanoma: a multicentre, open-label, phase 3 randomised
controlled trial. Lancet. 2012;380:358-365.
45. La Greca M, Grasso G, Antonelli G, et al. Neoadjuvant therapy for locally
advanced melanoma: new strategies with targeted therapies. Oncol
Targets Ther. 2014;7:1115-1121.
46. Rastrelli M, Pigozzo J, di Maggio A, et al. Neoadjuvant treatment with
dabrafenib of unresectable localizations from occult melanoma. Melanoma
Res. 2014;24:413-414.
47. Salama AK, Flaherty KT. BRAF in melanoma: current strategies and
future directions. Clin Cancer Res. 2013;19:4326-4334.
48. Hu-Lieskovan S, Robert L, Homet Moreno B, et al. Combining targeted
therapy with immunotherapy in BRAF-mutant melanoma: promise
and challenges. J Clin Oncol. 2014;32:2248-2254.
49. Storm FK, Sparks FC, Morton DL. Treatment for melanoma of the
lower extremity with intralesional injection of bacille Calmette Guérinand
hyperthermic perfusion. Surg Gynecol Obstet. 1979;149:17-21.
50. Mastrangelo MJ, Bellet RE, Berkelhammer J, et al. Regression of pulmonary
metastatic disease associated with intralesional BCG therapy of intracutaneous
melanoma metastases. Cancer. 1975;36:1305-1308.
51. Agarwala SS, Neuberg D, Park Y, et al. Mature results of a phase III
randomized trial of bacillus Calmette-Guerin (BCG) versus observation
and BCG plus dacarbazine versus BCG in the adjuvant therapy of American
Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of
the Eastern Oncology Group. Cancer. 2004;100:1692-1698.
52. Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene. 2003;22:
3188-3192.
53. von Wussow P, Block B, Hartmann F, et al. Intralesional interferonalpha
therapy in advanced malignant melanoma. Cancer. 1988;61:1071-
1074.
54. Kubo H, Ashida A, Matsumoto K, et al. Interferon-beta therapy for malignant
melanoma: the dose is crucial for inhibition of proliferation and
induction of apoptosis of melanoma cells. Arch Dermatol Res. 2008;300:
297-301.
55. Thompson JF, Agarwala SS, Smithers BM, et al. Phase 2 study of intralesional
PV-10 in refractory metastatic melanoma. Ann Surg Oncol.
Epub 2014 Oct 28.
56. Andtbacka RH, Curti BD, Kaufman H, et al. CALM study: A phase II
study of an intratumorally delivered oncolytic immunotherapeutic
agent, coxsackievirus A21, in patients with stage IIIc and stage IV malignant
melanoma. Paper presented at: 50th Annual Meeting of the
American Society of Clinical Oncology; May 30 to June 3, 2014; Chicago,
IL.
57. Bedikian AY, Richards J, Kharkevitch D, et al. A phase 2 study of highdose
allovectin-7 in patients with advanced metastatic melanoma. Melanoma
Res. 2010;20:218-226.
58. Kaufman HL, Andtbacka RH, Collichio FH, et al. Primary overall survival
(OS) from OPTiM, a randomized phase III trial of talimogene
laherparepvec (T-VEC) versus subcutaneous (SC) granulocytemacrophage
colony-stimulating factor (GM-CSF) for the treatment (tx)
of unresected stage IIIB/C and IV melanoma. Paper presented at: 50th
Annual Meeting of the American Society of Clinical Oncology; May 30
to June 3, 2014; Chicago, IL.
59. Schadendorf D, Hodi FS, Robert C, et al. Pooled Analysis of Long-Term
Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable
or Metastatic Melanoma. J Clin Oncol. Epub 2015 Feb 9.
60. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with
lambrolizumab (anti-PD-1) in melanoma. New Engl J Med. 2013;369:
134-144.
61. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated
melanoma without BRAF mutation. New Engl J Med. 2015;372:320-330.
62. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab
in advanced melanoma. New Engl J Med. 2013;369:122-133.
63. Hodi FS, Lee S, McDermott DF, et al. Ipilimumab plus sargramostim vs
ipilimumab alone for treatment of metastatic melanoma: a randomized
clinical trial. JAMA. 2014;312:1744-1753.
64. Hodi FS, Lawrence D, Lezcano C, et al. Bevacizumab plus ipilimumab in
patients with metastatic melanoma. Cancer Immunol Res. 2014;2:632-
642.
65. Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity
in patients treated with cytotoxic T lymphocyte-associated antigen
4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005;
12:1005-1016.
66. Sznol M, Kluger HM, Callahan MK, et al. Survival, response duration,
and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-
PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent
therapy in advanced melanoma (MEL). Paper presented at: 50th Annual
Meeting of the American Society of Clinical Oncology; May 30 to June 3,
2014; Chicago, IL.
67. Kirkwood JM, Butterfıeld LH, Tarhini AA, et al. Immunotherapy of
cancer in 2012. CA Cancer J Clin. 2012;62:309-335.
68. Sullivan RJ, Hoshida Y, Brunet J, et al. A single center experience with
high-dose IL-2 treatment for patients with advanced melanoma and pilot
investigation of a novel gene expression signature as a predictor of
response. J Clin Oncol. 2009;27:15s (suppl;abstr 9003).
69. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response
to CTLA-4 blockade in melanoma. New Engl J Med. 2014;371:
2189-2199.
70. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses
by inhibiting adaptive immune resistance. Nature. 2014;515:
568-571.
e542
2015 ASCO EDUCATIONAL BOOK | asco.org/edbook